| CAS NO: | 1227162-34-6 |
| 包装 | 价格(元) |
| 500 μg | 电议 |
| 1mg | 电议 |
| Cas No. | 1227162-34-6 |
| 别名 | 来那度胺-D5,CC-5013-d5 |
| Canonical SMILES | NC1=C(CN(C2([2H])C(NC(C([2H])([2H])C2([2H])[2H])=O)=O)C3=O)C3=CC=C1 |
| 分子式 | C13H8D5N3O3 |
| 分子量 | 264.3 |
| 溶解度 | DMSO: soluble,Methanol: soluble |
| 储存条件 | Store at -20°C |
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
| Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
| 产品描述 | Lenalidomide-d5is intended for use as an internal standard for the quantification of lenalidomide by GC- or LC-MS. Lenalidomide is related to thalidomide and, at 10 μM, alters gene expression and cell viability in a range of cancer cell lines.1It also induces proliferation and enhances the functional capacity of T lymphocytes, amplifying co-stimulatory signaling pathways.2Lenalidomide is effective in hematologic cancers, including lymphomas and myelomas.3,4 1.Kim, K., An, S., Cha, H.J., et al.Lenalidomide induces apoptosis and alters gene expression in non-small cell lung cancer cellsOncol.Lett.5(2)588-596(2013) 2.McDaniel, J.M., Pinilla-Ibarz, J., and Epling-Burnette, P.K.Molecular action of lenalidomide in lymphocytes and hematologic malignanciesAdv. Hematol.513702(2012) 3.Latif, T., Chauhan, N., Khan, R., et al.Thalidomide and its analogues in the treatment of multiple myelomaExp.Hermatol.Oncol.1(1)27(2012) 4.Merli, M., Ferrario, A., Basilico, C., et al.Novel agents in indolent lymphomasTher.Adv.Hematol.4(2)133-148(2013) |
m.cnreagent.com